Sandoz Lifted By Growth In Europe And Biosimilars

First-Half Sales Of Biosimilars Top A Billion Dollars For Sandoz After Double-Digit Increase

Double-digit growth in the Europe region and in its biosimilars business helped to push up sales for Sandoz in the second quarter and first half of 2023.

Sandoz logo on building
Sandoz has reported its first-half results • Source: Shutterstock

Sandoz has delivered first-half results that reflect the strength of its business in Europe and the continuing expansion of its biosimilars segment, with double-digit growth for both aspects of the business helping to push up its sales in both the second quarter and first half of 2023.

Second-quarter sales came in at $2.379bn – up 5% as reported and 8% at constant currencies – with volume contributing...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business